ATE499111T1 - Zusammensetzungen und verfahren zur oxalatreduktion - Google Patents

Zusammensetzungen und verfahren zur oxalatreduktion

Info

Publication number
ATE499111T1
ATE499111T1 AT06845574T AT06845574T ATE499111T1 AT E499111 T1 ATE499111 T1 AT E499111T1 AT 06845574 T AT06845574 T AT 06845574T AT 06845574 T AT06845574 T AT 06845574T AT E499111 T1 ATE499111 T1 AT E499111T1
Authority
AT
Austria
Prior art keywords
compositions
oxalate
hyperoxaluria
methods
disease
Prior art date
Application number
AT06845574T
Other languages
German (de)
English (en)
Inventor
Qingshan Li
Harmeet Sidhu
Original Assignee
Oxthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxthera Inc filed Critical Oxthera Inc
Application granted granted Critical
Publication of ATE499111T1 publication Critical patent/ATE499111T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/03—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with oxygen as acceptor (1.2.3)
    • C12Y102/03004—Oxalate oxidase (1.2.3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
    • C12Y208/03—CoA-transferases (2.8.3)
    • C12Y208/03016—Formyl-CoA transferase (2.8.3.16)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/23—Aspartic endopeptidases (3.4.23)
    • C12Y304/23002—Pepsin B (3.4.23.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01002—Oxalate decarboxylase (4.1.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01008—Oxalyl-CoA decarboxylase (4.1.1.8)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06845574T 2005-12-16 2006-12-15 Zusammensetzungen und verfahren zur oxalatreduktion ATE499111T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75089605P 2005-12-16 2005-12-16
PCT/US2006/047967 WO2007075447A2 (en) 2005-12-16 2006-12-15 Compositions and methods for oxalate reduction

Publications (1)

Publication Number Publication Date
ATE499111T1 true ATE499111T1 (de) 2011-03-15

Family

ID=38218470

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06845574T ATE499111T1 (de) 2005-12-16 2006-12-15 Zusammensetzungen und verfahren zur oxalatreduktion

Country Status (11)

Country Link
US (2) US8900575B2 (https=)
EP (2) EP2366402A1 (https=)
JP (1) JP5558002B2 (https=)
CN (3) CN101405022A (https=)
AT (1) ATE499111T1 (https=)
AU (1) AU2006329844B2 (https=)
CA (1) CA2633238A1 (https=)
DE (1) DE602006020347D1 (https=)
ES (1) ES2362897T3 (https=)
HK (1) HK1201151A1 (https=)
WO (1) WO2007075447A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
ES2362897T3 (es) 2005-12-16 2011-07-14 Oxthera, Inc. Composiciones y métodos para reducción del oxalato.
PT2046373E (pt) 2006-08-02 2013-05-06 Althea Technologies Inc Oxalato descarboxilase cristalizada e métodos de utilização
CN101554237B (zh) * 2009-03-16 2013-11-06 武汉康复得生物科技有限公司 植物纤维或微生物不溶组分中的草酸降解酶的制备方法
US8431122B2 (en) * 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
JP2012531186A (ja) * 2009-07-02 2012-12-10 オクステラ インテレクチュアル プロパティ エービー 組換えオキサレート分解酵素の精製及び単離並びにオキサレート分解酵素を含む噴霧乾燥粒子
DK2270138T3 (en) * 2009-07-02 2018-06-25 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate-degrading enzymes
EP2504428A4 (en) * 2009-11-25 2013-09-25 Captozyme Llc METHODS AND COMPOSITIONS FOR TREATING OXALATE RELATED DISEASES
ES2703513T3 (es) * 2011-04-07 2019-03-11 Histapharm Inc Composiciones enzimáticas orales para administración intestinal
WO2014113648A1 (en) 2013-01-18 2014-07-24 Allena Pharmaceuticals, Inc. Crystallized oxalate decarboxylase and methods of use
DK3003358T3 (da) 2013-06-07 2021-06-21 Allena Pharmaceuticals Inc Sammensætninger og anordninger til dialyse
EP3277099B9 (en) * 2015-04-02 2024-05-29 Oxidien Pharmaceuticals, Llc High efficiency oxalate-degrading enzymes for degradation of insoluble and soluble oxalate
CA3023042A1 (en) 2016-06-13 2017-12-21 Oxthera Intellectual Property Ab Compositions and methods for the treatment or prevention of oxalate-related disorders
WO2019092608A1 (en) * 2017-11-08 2019-05-16 Materias S.R.L. In situ gelifying powder
CN114903985A (zh) * 2021-02-10 2022-08-16 宁波倍益嘉生物科技有限公司 一种组合物及其在防治高草酸尿症方面的应用
GB2625234A (en) * 2021-09-09 2024-06-12 Unlocked Labs Inc Therapeutic engineered microbial cell systems and methods for treating conditions in which oxalate is detrimental
CN116444636B (zh) * 2023-04-17 2024-02-20 西南大学 抑制核盘菌的水稻OsGLP3-6及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205132A (en) 1978-07-17 1980-05-27 Microlife Technics, Inc. Lyophilization of bacteria
DE3030185A1 (de) 1980-08-07 1982-04-08 Kohlbecker, Günther, 3000 Hannover Verfahren zur enzymatischen entfernung von oxalat mittels oxalat-oxidase
DE3204284A1 (de) 1982-02-06 1983-08-18 Kohlbecker, Günther, 3000 Hannover Verfahren zur enzymatischen entfernung von sauerstoff
JPS5968344A (ja) 1982-10-12 1984-04-18 Agency Of Ind Science & Technol 非対称機能膜及びその製法
US4539118A (en) 1984-03-23 1985-09-03 Sigma Chemical Company Rapid, accurate method of separation of oxalate from urine and other biological fluids
US5263992A (en) 1986-10-17 1993-11-23 Bio-Metric Systems, Inc. Biocompatible device with covalently bonded biocompatible agent
US5427935A (en) * 1987-07-24 1995-06-27 The Regents Of The University Of Michigan Hybrid membrane bead and process for encapsulating materials in semi-permeable hybrid membranes
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5286495A (en) 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
EP0673416A1 (en) 1992-11-30 1995-09-27 Zeneca Limited Oxalate decarboxylase
EP0693884A4 (en) 1993-04-16 1996-03-27 Mccormick & Co Inc ENCLOSURE COMPOSITIONS
US5554147A (en) 1994-02-01 1996-09-10 Caphco, Inc. Compositions and devices for controlled release of active ingredients
US5788687A (en) 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
US5505713A (en) 1994-04-01 1996-04-09 Minimed Inc. Indwelling catheter with stable enzyme coating
EP0764204B1 (en) 1994-05-18 2001-08-22 Human Genome Sciences, Inc. HUMAN OXALYL-CoA DECARBOXYLASE
US6214980B1 (en) 1994-06-20 2001-04-10 University Of Florida Materials and methods for detection of Oxalobacte formigenes
US6090628A (en) 1994-06-20 2000-07-18 University Of Florida Materials and methods for detection of Oxalobactor formigenes
US5604111A (en) 1994-06-20 1997-02-18 University Of Florida Research Foundation Method and kit for detection of oxalate
US5912125A (en) 1994-06-20 1999-06-15 University Of Florida Materials and methods for detection of oxalobacter
US5916790A (en) * 1995-03-03 1999-06-29 Metabolex, Inc. Encapsulation compositions, and methods
US6033719A (en) 1996-04-25 2000-03-07 Medtronic, Inc. Method for covalent attachment of biomolecules to surfaces of medical devices
SE9603029D0 (sv) 1996-08-20 1996-08-20 Svenska Traeforskningsinst Method for lowering the level of oxalic acid
US7435425B2 (en) * 2001-07-17 2008-10-14 Baxter International, Inc. Dry hemostatic compositions and methods for their preparation
CA2266581C (en) * 1996-09-19 2007-03-13 The Regents Of The University Of Michigan Polymers containing polysaccharides such as alginates or modified alginates
US6297425B1 (en) 1997-03-21 2001-10-02 Pioneer Hi-Bred International, Inc. Gene encoding oxalate decarboxylase from aspergillus phoenices
US8486389B2 (en) * 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
US6355242B1 (en) 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
PT983076E (pt) * 1997-05-23 2010-01-05 Oxthera Inc Microrganismos de degradação de oxalato ou enzimas de degradação de oxalato para prevenir doenças relacionadas com oxalato
US20040120941A1 (en) * 1997-05-23 2004-06-24 Allison Milton J. Materials and methods for treating or preventing oxalate-related disease
US6161499A (en) * 1997-07-07 2000-12-19 Cvd Diamond Corporation Apparatus and method for nucleation and deposition of diamond using hot-filament DC plasma
US6080404A (en) 1997-09-05 2000-06-27 University Of Florida Materials and methods for removal of substances from fluids
US6566407B2 (en) 1997-11-05 2003-05-20 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
AU3743099A (en) * 1998-04-24 1999-11-16 Onyx Pharmaceuticals, Inc. Novel nucleic acids and polypeptides related to a farnesyl-directed cysteine carboxymethyltransferase
JP5068401B2 (ja) 1998-09-28 2012-11-07 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップ Ｈｐｍｃカプセルを使用する腸及び結腸への送達
DE69940821D1 (de) 1998-10-09 2009-06-10 Gen Mills Inc Verkapselung empfindlicher flüssiger komponenten in eine matrix zur gewinnung diskreter lagerbeständiger partikel
IT1309427B1 (it) 1999-05-28 2002-01-23 Mendes S U R L Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso
TR200103540T2 (tr) 1999-06-07 2002-04-22 Nanosphere Inc. Partikül kaplama yöntemleri ve bu şekilde üretilen partiküller.
NZ526443A (en) 2000-12-18 2005-03-24 Probiohealth Llc Probiotic compounds derived from lactobacillus casei strain KE01
US7407668B2 (en) 2002-01-24 2008-08-05 Boston Scimed, Inc. Medical articles having enzymatic surfaces for localized therapy
US6929940B1 (en) 2002-08-20 2005-08-16 University Of Florida Research Foundation, Inc. Polynucleotides encoding oxalate decarboxylase from Aspergillus niger and methods of use
NL1021879C2 (nl) * 2002-11-08 2004-05-11 Univ Delft Tech Werkwijze voor het bereiden van vernette enzymdeeltjes.
WO2005060937A1 (en) 2003-12-23 2005-07-07 Chr. Hansen A/S Compressed tablets comprising viable probiotic microorganisms
EP1755655A4 (en) * 2004-05-07 2011-03-30 Oxthera Inc METHOD AND COMPOSITIONS FOR REDUCING OXALATE CONCENTRATIONS
PT1962873E (pt) 2005-12-14 2013-08-29 Oxthera Inc Composições farmacêuticas compreendendo bactérias redutoras de oxalato
ES2362897T3 (es) 2005-12-16 2011-07-14 Oxthera, Inc. Composiciones y métodos para reducción del oxalato.
PT2046373E (pt) 2006-08-02 2013-05-06 Althea Technologies Inc Oxalato descarboxilase cristalizada e métodos de utilização
US8431122B2 (en) 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes

Also Published As

Publication number Publication date
WO2007075447A3 (en) 2008-12-24
CN101405022A (zh) 2009-04-08
EP2366402A1 (en) 2011-09-21
JP2009519950A (ja) 2009-05-21
DE602006020347D1 (de) 2011-04-07
EP1976553B1 (en) 2011-02-23
AU2006329844B2 (en) 2012-11-15
AU2006329844A8 (en) 2008-07-31
CN107638563A (zh) 2018-01-30
AU2006329844A1 (en) 2007-07-05
HK1201151A1 (en) 2015-08-28
US20150125538A1 (en) 2015-05-07
WO2007075447A2 (en) 2007-07-05
EP1976553A4 (en) 2009-09-23
US8900575B2 (en) 2014-12-02
US20070184118A1 (en) 2007-08-09
ES2362897T3 (es) 2011-07-14
JP5558002B2 (ja) 2014-07-23
US10272043B2 (en) 2019-04-30
CA2633238A1 (en) 2007-07-05
HK1128613A1 (en) 2009-11-06
CN104013581A (zh) 2014-09-03
EP1976553A2 (en) 2008-10-08

Similar Documents

Publication Publication Date Title
ATE499111T1 (de) Zusammensetzungen und verfahren zur oxalatreduktion
PT1773361E (pt) Composição baseada em bactérias probióticas e sua utilização na prevenção e/ou tratamento de patologias e/ou infecções respiratórias e na melhoria da funcionalidade intestinal
ZA200801706B (en) Methods and compositions for the prevention and treatment of kidney disease
CY1118006T1 (el) Χρηση γαλακτοβακιλλων για την αγωγη ιικων λοιμωξεων
EP2047863A4 (en) MEANS FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES
BRPI0717219A2 (pt) "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
WO2008043107A3 (en) Use of tight junction antagonists to treat inflammatory bowel disease
BRPI0817905A2 (pt) Utilização de uma cepa de bifidobacterium, para o preparo de uma composição destinada à prevenção e/ou ao tratamento de manifestações do tipo alérgicas
ZA200800452B (en) Methods and compositions for the prevention and treatment of kidney disease
BRPI0807046A2 (pt) Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.
BRPI0817063A2 (pt) "métodos de inibição, para o tratamento de uma condição patológica, para a inibição de linfagiogênese tumoral, de inibição ou prevenção,de desorganização, para inibição de crescimento de tumor, de tratamento, de acentuação da eficácia de um agente anti-angiogênese e antagonista de alk-1
WO2010115092A3 (en) Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer
CL2007003332A1 (es) Compuestos derivados de heterociclos condensados; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o tratamiento de infecciones bacterianas.
SG158145A1 (en) Vaccines against chlamydial infection
IL189270A0 (en) Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
EP2192920A4 (en) METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING RADIATION-INDUCED FIBROSIS
WO2008088524A3 (en) Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor
EP2076284A4 (en) METHOD FOR THE TREATMENT, PREVENTION AND DIAGNOSIS OF TTV INFECTION IN PIGS
PL1732575T3 (pl) Związki zawierające stron do stosowania w zapobieganiu lub leczeniu stanów nekrotycznych kości
EP2666480A3 (en) Uses and compositions for treatment of Crohn's desease
EP2097440A4 (en) ANTIBIOTICS BASED ON GLYCOPEPTIDES AND LIPOGLYCOPEPTIDES PHOSPHONES AND THEIR USES IN THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS
WO2009042642A3 (en) Compositions and methods for the treatment and prevention of ulcerative colitis and colon cancer
EP1868437A4 (en) METHOD FOR TREATING OR PREVENTING BONE REMOVAL OR OSTEOPOROSIS
EP1874130A4 (en) METHOD AND COMPOSITIONS FOR PREVENTING AND TREATING NURSE DISEASES
IL186672A0 (en) Phosphonated fluoroquinolones, antibacterial analogs thereof, and methods for the prevention and treatment of bone and joint infections

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties